{"id":7212,"date":"2020-01-30T11:51:48","date_gmt":"2020-01-30T10:51:48","guid":{"rendered":"https:\/\/inovie.fr\/imagenome-v2\/?p=7212"},"modified":"2020-01-30T11:51:48","modified_gmt":"2020-01-30T10:51:48","slug":"imagenome-propose-un-test-pan-cancer-sur-adn-tumoral-et-adn-circulant","status":"publish","type":"post","link":"https:\/\/imagenome.fr\/2020\/01\/30\/imagenome-propose-un-test-pan-cancer-sur-adn-tumoral-et-adn-circulant\/","title":{"rendered":"Imagenome propose un test pan-cancer sur ADN tumoral et ADN circulant"},"content":{"rendered":"

Labosud, via son p\u00f4le de sp\u00e9cialit\u00e9 Imagenome, est le premier laboratoire fran\u00e7ais \u00e0 proposer un test pan-cancer sur ADN tumoral tissulaire et ADN circulant accompagn\u00e9 d’un conseil personnalis\u00e9.<\/strong><\/p>\n

FoundationOne CDX<\/strong> et FoundationOne Liquid<\/strong> sont des profils g\u00e9nomiques complets et valid\u00e9s qui interrogent les <\/span>s\u00e9quences codantes enti\u00e8res et certains remaniements de g\u00e8nes li\u00e9s au cancer<\/span>.<\/span> Ces tests identifient, sur la tumeur ou dans le sang<\/span> pour un suivi sans biopsie, toutes les alt\u00e9rations cliniquement pertinentes \u00e9largissant souvent les options de traitement en faisant correspondre chaque<\/span> anomalie avec des th\u00e9rapies cibl\u00e9es et des essais cliniques qui sont pertinents en fonction de l’\u00e9volution de la maladie. <\/span><\/span><\/div>\n
<\/div>\n
Les tests sont compl\u00e9t\u00e9s par un conseil personnalis\u00e9 par un g\u00e9n\u00e9ticien mol\u00e9culaire sp\u00e9cialis\u00e9e en oncologie<\/strong>. <\/span><\/span><\/div>\n
<\/div>\n
Ces tests sont r\u00e9alis\u00e9s en collaboration avec Roche SAS : consulter leur site internet<\/a><\/em><\/div>\n
<\/div>\n

 <\/p>\n","protected":false},"excerpt":{"rendered":"

Labosud, via son p\u00f4le de sp\u00e9cialit\u00e9 Imagenome, est le premier laboratoire fran\u00e7ais \u00e0 proposer un test pan-cancer sur ADN tumoral tissulaire et ADN circulant accompagn\u00e9 d’un conseil personnalis\u00e9. FoundationOne CDX et FoundationOne Liquid sont des profils g\u00e9nomiques complets et valid\u00e9s … Continue reading →<\/span><\/a><\/p>\n","protected":false},"author":21,"featured_media":7213,"comment_status":"closed","ping_status":"closed","sticky":true,"template":"","format":"standard","meta":{"inline_featured_image":false,"_links_to":"","_links_to_target":""},"categories":[1],"tags":[],"acf":[],"yoast_head":"\nImagenome propose un test pan-cancer sur ADN tumoral et ADN circulant - Imagenome<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/imagenome.fr\/2020\/01\/30\/imagenome-propose-un-test-pan-cancer-sur-adn-tumoral-et-adn-circulant\/\" \/>\n<meta property=\"og:locale\" content=\"fr_FR\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Imagenome propose un test pan-cancer sur ADN tumoral et ADN circulant - Imagenome\" \/>\n<meta property=\"og:description\" content=\"Labosud, via son p\u00f4le de sp\u00e9cialit\u00e9 Imagenome, est le premier laboratoire fran\u00e7ais \u00e0 proposer un test pan-cancer sur ADN tumoral tissulaire et ADN circulant accompagn\u00e9 d’un conseil personnalis\u00e9. FoundationOne CDX et FoundationOne Liquid sont des profils g\u00e9nomiques complets et valid\u00e9s … Continue reading →\" \/>\n<meta property=\"og:url\" content=\"https:\/\/imagenome.fr\/2020\/01\/30\/imagenome-propose-un-test-pan-cancer-sur-adn-tumoral-et-adn-circulant\/\" \/>\n<meta property=\"og:site_name\" content=\"Imagenome\" \/>\n<meta property=\"article:published_time\" content=\"2020-01-30T10:51:48+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/imagenome.fr\/wp-content\/uploads\/sites\/47\/2020\/01\/News-Imagenome-30012020-1024x973.png\" \/>\n\t<meta property=\"og:image:width\" content=\"1024\" \/>\n\t<meta property=\"og:image:height\" content=\"973\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/png\" \/>\n<meta name=\"author\" content=\"Labosud Groupe Communication\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"\u00c9crit par\" \/>\n\t<meta name=\"twitter:data1\" content=\"Labosud Groupe Communication\" \/>\n\t<meta name=\"twitter:label2\" content=\"Dur\u00e9e de lecture estim\u00e9e\" \/>\n\t<meta name=\"twitter:data2\" content=\"1 minute\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\/\/schema.org\",\"@graph\":[{\"@type\":\"WebPage\",\"@id\":\"https:\/\/imagenome.fr\/2020\/01\/30\/imagenome-propose-un-test-pan-cancer-sur-adn-tumoral-et-adn-circulant\/\",\"url\":\"https:\/\/imagenome.fr\/2020\/01\/30\/imagenome-propose-un-test-pan-cancer-sur-adn-tumoral-et-adn-circulant\/\",\"name\":\"Imagenome propose un test pan-cancer sur ADN tumoral et ADN circulant - Imagenome\",\"isPartOf\":{\"@id\":\"https:\/\/imagenome.fr\/#website\"},\"datePublished\":\"2020-01-30T10:51:48+00:00\",\"dateModified\":\"2020-01-30T10:51:48+00:00\",\"author\":{\"@id\":\"https:\/\/imagenome.fr\/#\/schema\/person\/49006d15238e00543cff98db08aaf206\"},\"breadcrumb\":{\"@id\":\"https:\/\/imagenome.fr\/2020\/01\/30\/imagenome-propose-un-test-pan-cancer-sur-adn-tumoral-et-adn-circulant\/#breadcrumb\"},\"inLanguage\":\"fr-FR\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\/\/imagenome.fr\/2020\/01\/30\/imagenome-propose-un-test-pan-cancer-sur-adn-tumoral-et-adn-circulant\/\"]}]},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\/\/imagenome.fr\/2020\/01\/30\/imagenome-propose-un-test-pan-cancer-sur-adn-tumoral-et-adn-circulant\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\/\/imagenome.fr\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Imagenome propose un test pan-cancer sur ADN tumoral et ADN circulant\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\/\/imagenome.fr\/#website\",\"url\":\"https:\/\/imagenome.fr\/\",\"name\":\"Imagenome\",\"description\":\"Tests g\u00e9n\u00e9tiques innovants pour une prise en charge personnalis\u00e9e\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\/\/imagenome.fr\/?s={search_term_string}\"},\"query-input\":\"required name=search_term_string\"}],\"inLanguage\":\"fr-FR\"},{\"@type\":\"Person\",\"@id\":\"https:\/\/imagenome.fr\/#\/schema\/person\/49006d15238e00543cff98db08aaf206\",\"name\":\"Labosud Groupe Communication\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"fr-FR\",\"@id\":\"https:\/\/imagenome.fr\/#\/schema\/person\/image\/\",\"url\":\"https:\/\/secure.gravatar.com\/avatar\/41dce42773c69f757749bb4e4d657217?s=96&d=mm&r=g\",\"contentUrl\":\"https:\/\/secure.gravatar.com\/avatar\/41dce42773c69f757749bb4e4d657217?s=96&d=mm&r=g\",\"caption\":\"Labosud Groupe Communication\"},\"sameAs\":[\"http:\/\/labosud.com\"],\"url\":\"https:\/\/imagenome.fr\/author\/labosud-groupe\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Imagenome propose un test pan-cancer sur ADN tumoral et ADN circulant - Imagenome","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/imagenome.fr\/2020\/01\/30\/imagenome-propose-un-test-pan-cancer-sur-adn-tumoral-et-adn-circulant\/","og_locale":"fr_FR","og_type":"article","og_title":"Imagenome propose un test pan-cancer sur ADN tumoral et ADN circulant - Imagenome","og_description":"Labosud, via son p\u00f4le de sp\u00e9cialit\u00e9 Imagenome, est le premier laboratoire fran\u00e7ais \u00e0 proposer un test pan-cancer sur ADN tumoral tissulaire et ADN circulant accompagn\u00e9 d’un conseil personnalis\u00e9. FoundationOne CDX et FoundationOne Liquid sont des profils g\u00e9nomiques complets et valid\u00e9s … Continue reading →","og_url":"https:\/\/imagenome.fr\/2020\/01\/30\/imagenome-propose-un-test-pan-cancer-sur-adn-tumoral-et-adn-circulant\/","og_site_name":"Imagenome","article_published_time":"2020-01-30T10:51:48+00:00","og_image":[{"width":1024,"height":973,"url":"https:\/\/imagenome.fr\/wp-content\/uploads\/sites\/47\/2020\/01\/News-Imagenome-30012020-1024x973.png","type":"image\/png"}],"author":"Labosud Groupe Communication","twitter_card":"summary_large_image","twitter_misc":{"\u00c9crit par":"Labosud Groupe Communication","Dur\u00e9e de lecture estim\u00e9e":"1 minute"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"WebPage","@id":"https:\/\/imagenome.fr\/2020\/01\/30\/imagenome-propose-un-test-pan-cancer-sur-adn-tumoral-et-adn-circulant\/","url":"https:\/\/imagenome.fr\/2020\/01\/30\/imagenome-propose-un-test-pan-cancer-sur-adn-tumoral-et-adn-circulant\/","name":"Imagenome propose un test pan-cancer sur ADN tumoral et ADN circulant - Imagenome","isPartOf":{"@id":"https:\/\/imagenome.fr\/#website"},"datePublished":"2020-01-30T10:51:48+00:00","dateModified":"2020-01-30T10:51:48+00:00","author":{"@id":"https:\/\/imagenome.fr\/#\/schema\/person\/49006d15238e00543cff98db08aaf206"},"breadcrumb":{"@id":"https:\/\/imagenome.fr\/2020\/01\/30\/imagenome-propose-un-test-pan-cancer-sur-adn-tumoral-et-adn-circulant\/#breadcrumb"},"inLanguage":"fr-FR","potentialAction":[{"@type":"ReadAction","target":["https:\/\/imagenome.fr\/2020\/01\/30\/imagenome-propose-un-test-pan-cancer-sur-adn-tumoral-et-adn-circulant\/"]}]},{"@type":"BreadcrumbList","@id":"https:\/\/imagenome.fr\/2020\/01\/30\/imagenome-propose-un-test-pan-cancer-sur-adn-tumoral-et-adn-circulant\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/imagenome.fr\/"},{"@type":"ListItem","position":2,"name":"Imagenome propose un test pan-cancer sur ADN tumoral et ADN circulant"}]},{"@type":"WebSite","@id":"https:\/\/imagenome.fr\/#website","url":"https:\/\/imagenome.fr\/","name":"Imagenome","description":"Tests g\u00e9n\u00e9tiques innovants pour une prise en charge personnalis\u00e9e","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/imagenome.fr\/?s={search_term_string}"},"query-input":"required name=search_term_string"}],"inLanguage":"fr-FR"},{"@type":"Person","@id":"https:\/\/imagenome.fr\/#\/schema\/person\/49006d15238e00543cff98db08aaf206","name":"Labosud Groupe Communication","image":{"@type":"ImageObject","inLanguage":"fr-FR","@id":"https:\/\/imagenome.fr\/#\/schema\/person\/image\/","url":"https:\/\/secure.gravatar.com\/avatar\/41dce42773c69f757749bb4e4d657217?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/41dce42773c69f757749bb4e4d657217?s=96&d=mm&r=g","caption":"Labosud Groupe Communication"},"sameAs":["http:\/\/labosud.com"],"url":"https:\/\/imagenome.fr\/author\/labosud-groupe\/"}]}},"_links":{"self":[{"href":"https:\/\/imagenome.fr\/wp-json\/wp\/v2\/posts\/7212"}],"collection":[{"href":"https:\/\/imagenome.fr\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/imagenome.fr\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/imagenome.fr\/wp-json\/wp\/v2\/users\/21"}],"replies":[{"embeddable":true,"href":"https:\/\/imagenome.fr\/wp-json\/wp\/v2\/comments?post=7212"}],"version-history":[{"count":0,"href":"https:\/\/imagenome.fr\/wp-json\/wp\/v2\/posts\/7212\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/imagenome.fr\/wp-json\/wp\/v2\/media\/7213"}],"wp:attachment":[{"href":"https:\/\/imagenome.fr\/wp-json\/wp\/v2\/media?parent=7212"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/imagenome.fr\/wp-json\/wp\/v2\/categories?post=7212"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/imagenome.fr\/wp-json\/wp\/v2\/tags?post=7212"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}